Provided by Tiger Trade Technology Pte. Ltd.

Zevra Therapeutics

8.57
-0.0300-0.35%
Volume:523.90K
Turnover:4.48M
Market Cap:482.47M
PE:14.50
High:8.70
Open:8.55
Low:8.37
Close:8.60
52wk High:13.16
52wk Low:6.19
Shares:56.30M
Float Shares:47.46M
Volume Ratio:0.61
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.5910
EPS(LYR):-2.2813
ROE:34.81%
ROA:-7.84%
PB:3.62
PE(LYR):-3.76

Loading ...

Timothy J. Sangiovanni, SVP Finance & Corp Controller, Reports Disposal of Zevra Therapeutics Inc. Common Shares

Reuters
·
Feb 05

Zevra Therapeutics CCO Joshua Schafer Reports Sale of Common Shares

Reuters
·
Feb 05

Zevra Therapeutics präsentiert positive Langzeitdaten zu MIPLYFFA bei Niemann-Pick Typ C

Reuters
·
Feb 04

Zevra Therapeutics Chief Medical Officer Adrian Quartel Reports Disposal of Common Shares

Reuters
·
Feb 03

Zevra Therapeutics to Ring Nasdaq Opening Bell

Reuters
·
Feb 02

Zevra Therapeutics Unveils Four-Year Real-World Data on MIPLYFFA for Niemann-Pick Disease Type C

Reuters
·
Jan 26

Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story?

Simply Wall St.
·
Jan 15

A Look At Zevra Therapeutics (ZVRA) Valuation After New Uniphar MIPLYFFA Access Agreement

Simply Wall St.
·
Jan 06

BRIEF-Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC)

Reuters
·
Dec 29, 2025

Zevra Therapeutics Signs Distribution Agreement with Uniphar for MIPLYFFA Access

Reuters
·
Dec 29, 2025

Zevra Therapeutics Inc - Agreement Enables Npc Patients to Access Miplyffa Outside Europe

THOMSON REUTERS
·
Dec 29, 2025

Zevra Therapeutics Inc - Appoints Timothy Sangiovanni as Interim Principal Financial Officer - SEC Filing

THOMSON REUTERS
·
Dec 18, 2025

Zevra Therapeutics Names Timothy Sangiovanni Interim Principal Financial Officer

Reuters
·
Dec 18, 2025

Zevra Therapeutics Grants Stock Options to New Employees Under Inducement Award Plan

Reuters
·
Dec 13, 2025

Zevra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 13, 2025

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 13, 2025

Zevra Therapeutics Files Initial Beneficial Ownership Statement; Alicia Secor Named as Director and Reporting Person

Reuters
·
Dec 10, 2025

Does Zevra Therapeutics’ (ZVRA) Board Turnover Subtly Recast Its Leadership and Capital Allocation Narrative?

Simply Wall St.
·
Dec 04, 2025

Press Release: Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Dow Jones
·
Dec 02, 2025

Zevra Therapeutics (ZVRA): Assessing Valuation After CFO Succession News Spurs Fresh Investor Interest

Simply Wall St.
·
Nov 25, 2025